US-Listed Public Company Profile built from SEC and market records · June 2026

BridgeBio Pharma, Inc. (BBIO)

$68.15 -0.60% NASDAQ: BBIO · 15-min delayed

PALO ALTO, California
Public · NASDAQ: BBIO
839 employees

Visit website Follow

$16.5BMarket cap

$502.1MRevenue · FY2025

-$69.0KNet income

839Employees

BBIONASDAQ

2019IPO

About BridgeBio Pharma, Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: BBIO
Employees: 839
IPO date: Jun 27, 2019
Headquarters: 3160 PORTER DR.
PALO ALTO, California 94304
Phone: (650) 391-9740
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 54930028YG89VTY2J114

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Is BridgeBio Pharma, Inc. an American company? Yes. BridgeBio Pharma, Inc. is incorporated in Delaware, United States and headquartered in Palo Alto, California. Its legal-entity record reports no foreign parent — the company is independently American-owned.

Registry IDs

Ticker: BBIO Nasdaq
SEC CIK: 1743881
LEI: 54930028YG89VTY2J114
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show BridgeBio Pharma, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/bridgebio-pharma-inc/"><img src="https://americancompanies.com/badge/bridgebio-pharma-inc.svg" alt="BridgeBio Pharma, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow BridgeBio Pharma, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $502.1M
Net income: -$69.0K
Total assets: $936.0M
Market cap: $16.5B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: BBIO

$68.15 -0.60%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$49.00 $90.17

52-week range

Market cap: $16.5B
Shares outstanding: 241.5M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jun 27, 2019

BridgeBio Pharma, Inc. (BBIO) Stock Price

Reported a net loss of $69.0K in FY2025.
Trading 24% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review BridgeBio Pharma, Inc..

Write a review

Newsroom

News about BridgeBio Pharma, Inc.

4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now Zacks Investment Research · 2026-10-20 · positive Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records GlobeNewswire Inc. · 2026-10-11 · positive Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 GlobeNewswire Inc. · 2026-10-11 · positive FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing Zacks Investment Research · 2026-10-07 · positive BioMarin Stops Voxzogo Development for Noonan Syndrome Zacks Investment Research · 2026-09-16 · positive How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset Zacks Investment Research · 2026-09-03 · neutral

News & sentiment via Polygon.io

FAQ

BridgeBio Pharma, Inc.: frequently asked questions

Is BridgeBio Pharma, Inc. an American company?

Yes — BridgeBio Pharma, Inc. is an American company. BridgeBio Pharma, Inc. is incorporated in Delaware, United States and headquartered in Palo Alto, California. Its legal-entity record reports no foreign parent — the company is independently American-owned.

Where is BridgeBio Pharma, Inc. incorporated?

BridgeBio Pharma, Inc. is legally incorporated in Delaware, United States, according to its GLEIF legal-entity record.

Who owns BridgeBio Pharma, Inc.?

BridgeBio Pharma, Inc. reports no parent company in its legal-entity record — it is independently owned rather than a subsidiary.

Is BridgeBio Pharma, Inc. traded on a US stock exchange?

Yes — BridgeBio Pharma, Inc. trades under the ticker BBIO on the NASDAQ.

Where is BridgeBio Pharma, Inc. headquartered?

BridgeBio Pharma, Inc. is headquartered in Palo Alto, California, United States.

Is BridgeBio Pharma, Inc. publicly traded?

Yes — BridgeBio Pharma, Inc. is a publicly traded company. Its stock trades under the ticker symbol BBIO on the NASDAQ.

What does BridgeBio Pharma, Inc. do?

BridgeBio Pharma, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.